 arch conformability, and in the near
future the TX2 LP (low-profile), which will decrease the
profile of the delivery catheter and broaden the range of
available diameters. Medtronic (Santa Rosa, Calif) will
introduce the Valiant thoracic endograft with the Captivia delivery system, which should enhance the stability
and reliability of the deployment mechanism. W. L. Gore
(Flagstaff, Ariz) is currently conducting clinical trials of
